Taipale H, Solmi M, Lähteenvuo M, et al. - Researchers herein reported correlation between receiving treatment with prolactin-increasing antipsychotics and increased odds of breast cancer.

• A nested case-control study was performed using data from Finnish nationwide registers of hospital treatment, prescription drug purchases, and cancer diagnoses.

• From 1972 and 2014, 30,785 women were identified who were diagnosed with schizophrenia; breast cancer was diagnosed in 1,069 of these women between January 1, 2000, and December 31, 2017.

• The cases were matched by age and duration of illness to a total of 5,339 women without cancer (controls).

• Increased odds of breast cancer are recorded in significant correlation with long-term exposure to prolactin-increasing, but not to prolactin-sparing, antipsychotics.

• Long-term use of prolactin-increasing antipsychotics is linked with greater risk of developing lobular adenocarcinoma than that of developing ductal adenocarcinoma.

• In women with schizophrenia receiving treatment with prolactin-increasing antipsychotics, it is paramount to monitor prolactinemia and address hyperprolactinemia.